Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.43 |
| ▸ | CTSS | P25774 | 11/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419788 | 0.84 | CASP3 (0.46) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL3323682 | 0.80 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL1486220 | 0.80 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL688341 | 0.80 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL8354998 | 0.80 | CYP1A2 (0.45) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL14984731 | 0.79 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL1235161 | 0.79 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL4279525 | 0.79 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL1235160 | 0.79 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL168105 | 0.79 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799552-B2 | Methods for treating diabetic neurotherapy | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2560629-B1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-05-05 | — | — | US | disclosed |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-07-18 | — | — | US | disclosed |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20190099467-A1 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-04-04 | — | — | US | disclosed |
| US-10149884-B2 | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-12-11 | — | — | US | disclosed |
| US-10022419-B2 | Methods for treating spinal cord injury | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-07-17 | — | — | US | disclosed |
| US-9993517-B2 | Methods and compositions for preserving retinal ganglion cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-06-12 | — | — | US | disclosed |
| US-20060263809-A1 | Method for sensitive measure of low level apoptosis in cells | THE RGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-11-23 | — | — | US | disclosed |
| US-20050129684-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2005-06-16 | — | — | US | disclosed |
| US-20040265300-A1 | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) | INSTITUT PASTEUR (FR) | 2004-12-30 | — | — | US | disclosed |
| US-20040192889-A1 | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-30 | — | — | US | disclosed |
| WO-2002092788-A9 | CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF | BUCK INST (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1392340-A2 | CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF | Buck Institute (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003061519-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030119038-A1 | NARC1, novel subtilase-like homologs | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-20030077826-A1 | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) | EDELMAN LENA (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2002092788-A2 | CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF | BUCK INSTITUTE (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099467-A1 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | GAP43, PDE6C, NGF | CTSK 554/4885CTSS 774/4885CTSL 1680/4885 |
| US-10022419-B2 | Methods for treating spinal cord injury | NGF, GAP43, BDNF | CTSK 262/4885CTSS 214/4885CTSL 977/4885 |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, PDE6B, PDE6C | CTSK 1652/4885CTSS 1861/4885CTSL 1670/4885 |
| US-10149884-B2 | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | ALDH1A2, PDE6B, PDE6C | CTSK 1652/4885CTSS 1861/4885CTSL 1670/4885 |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | NGF, GAP43, BDNF | CTSK 262/4885CTSS 214/4885CTSL 977/4885 |
| US-10799552-B2 | Methods for treating diabetic neurotherapy | NGF, NTRK2, BDNF | CTSK 248/4885CTSS 156/4885CTSL 1049/4885 |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | GAP43, PDE6C, NGF | CTSK 554/4885CTSS 774/4885CTSL 1680/4885 |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | ALDH1A2, PDE6B, PDE6A | CTSK 1839/4885CTSS 2121/4885CTSL 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.